Table 2.
Summary of vaccine and immune checkpoint trials highlighted in manuscript.
| NCT number | Phase | Patients | Treatment | OS | PFS | Reference |
|---|---|---|---|---|---|---|
| Vaccine | ||||||
| 3 | Newly Dx GBM | RT/TMZ/rindopepimut RT/TMZ |
20.1 mo 20.0 mo |
7.1 5.6 |
13 | |
| 1 | DIPG | H3K27M | NA | NA | NA | |
| 1 | IDH1 mutated recurrent grade 2 glioma | PEPIDH1M/tetanus-diphtheria toxoid/TMZ | NA | NA | NA | |
| 1 | Newly Dx IDHR132H mutated grade 3 and 4 astrocytoma | IDH vaccine/topical imiquimod+/−TMZ+/−RT | NA | NA | NA | |
| 2 | Recurrent GBM | HSPPC96/bevacizumab bevacizumab |
7.5 mo 10.7 mo |
NA | 35 | |
| 2 | Recurrent GBM | HSPPC96 | 42.6 wks | 19.1 wks | 34 | |
| 3 | Newly Dx GBM | DCVax | 23.1 mo* | NA | 36,37 | |
| 1 | Newly Dx MGMT unmethylated GBM | RT/NeoVax/pembrolizumab | NA | NA | 39 | |
| 2 | Recurrent GBM | bevacizumab/rindopepimut bevacizumab |
NA | NA | 40 | |
| 1 | Newly Dx GBM | APVAC1/APVAC2/polyICLC/GM-CSF/TMZ | NA | NA | 41 | |
| 1 | Newly Dx MGMT unmethylated GBM | RT/GNOS-PV01/INO-9012/nivolumab+/−ipilimumab | NA | NA | 42 | |
| 1 | GBM or DIPG | cyclophosphamide/bevacizumab/DC vaccine | NA | NA | NA | |
| 1 | DIPG | H3K27M | NA | NA | NA | |
| 1 | IDH1 mutated recurrent grade 2 glioma | PEPIDH1M/tetanus-diphtheria toxoid/TMZ | NA | NA | NA | |
| 1 | Newly Dx IDHR132H mutated grade 3 and 4 astrocytoma | IDH vaccine/topical imiquimod+/−TMZ+/−RT | NA | NA | NA | |
| Immune Checkpoint Inhibitor | ||||||
| 1 | Recurrent GBM | Neoadjuvant pembrolizumab | 417 days 228.5 days |
99.5 days 72.5 days |
14 | |
| 2 | Recurrent GBM | Neoadjuvant nivolumab | 7.3 mo | 4.1 mo | 15 | |
| 3 | Recurrent GBM | nivolumab bevacizumab |
9.8 mo 10.0 mo |
1.5 mo 3.5 mo |
44 | |
| 3 | Newly Dx MGMT unmethylated GBM | nivolumab | NA | NA | 45 | |
| 3 | Newly Dx MGMT methylated GBM | nivolumab | NA | NA | 46 | |
| 1 | Recurrent GBM | atezolizumab | 4.2 | 1.2 | 48 |
OS, overall survival; PFS, progression free survival; Dx, diagnosed; GBM, glioblastoma; RT, radiotherapy; TMZ, temozolomide; GM-CSF, granulocyte-macrophage colony-stimulating factor; DIPG, diffuse intrinsic pontine glioma; IDH1, isocitrate dehydrogenase 1;APVAC1, personalized vaccine; APVAC2, personalized vaccine; PEPIDH1M, IDH1 targeting vaccine; HSPPC96, heat shock peptide protein complex 96; DCvax, dendritic cell vaccine; NeoVax, personalized vaccine; GNOS-PV01, personalized vaccine; INO-9012, liposomal IL-12; mo, months; wks, weeks; GPVAC, glioma actively personalized vaccine consortium; NA, not available; MGMT, methyl guanine methyl transferase; DC vaccine, dendritic cell vaccine.
for the overall study population (combining the investigational arm and the standard of care arm)